AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $13.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$13.1M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 0 cutMore adding
Key stats
Fundamentals Sep 30- 52-wk high
- $19.10
- 52-wk low
- $12.77
- Mkt cap
- $59.11B
- Fwd P/E
- 11.5x
- Beta
- 0.10
- Div yield
- 3.26%
- P/S
- 0.0x
- P/B
- 1.3x
- Profit margin
- -3.5%
- Op margin
- +16.5%
- ROE
- -2.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TAK filings
Are insiders buying or selling Takeda Pharmaceutical Co Ltd ADR (TAK) stock?
Net selling: insiders sold $13.1M and bought $0 of TAK stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $2.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Plump, Andrew Stewart (President, R&D), who sold $5.3M. The latest filing was on Sep 16, 2026.
Which members of Congress have traded TAK recently?
None. No member of Congress disclosed a TAK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TAK smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
What funds are doing
How top traders are positioned
No tracked top-trader positions in TAK right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
Financials
The three statements
Technicals
Price structure
No verified market data for this stock yet.